Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Gastric Cancer × rucaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 10 Fallopian Tube Neoplasms 10 Breast Neoplasms 8 Prostatic Neoplasms 6 Neoplasms 6 Endometrial Neoplasms 5 Carcinoma, Ovarian Epithelial 5 Pancreatic Neoplasms 4 Uterine Cervical Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Recurrence 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Sarcoma 1 Prostate Cancer Metastatic 1 Primary Myelofibrosis 1 Pathologic Complete Response 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer 1

Interventions

Paclitaxel 9 apatinib 7 Oxaliplatin 6 Capecitabine 6 camrelizumab 5 S 1 (combination) 4 Cisplatin 4 Fluorouracil 3 130-nm albumin-bound paclitaxel 3 titanium silicide 2 Leucovorin 2 Drug Therapy 2 Docetaxel 2 vorolanib 1 spartalizumab 1 rucaparib 1 relatlimab 1 raltitrexed 1 pazopanib 1 olaparib 1 lobaplatin 1 linrodostat 1 ezogabine 1 endostar protein 1 durvalumab 1 dacomitinib 1 capivasertib 1 Sunitinib 1 Ramucirumab 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02935634 2023-06-09

FRACTION-GC

Bristol-Myers Squibb

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡